Mukka Proteins Ltd

Mukka Proteins Ltd has received an appellate order from the Commissioner of Income Tax (Appeals)-2, Panaji, concerning its appeal against an assessment order for AY 2018-19. The company was assessed with additions for alleged excess stock (₹11,14,72,010) and prior period income (₹4,48,21,141). The appellate order partly allowed the appeal, deleting the prior period income addition and ₹3,60,16,402 of the excess stock addition. However, ₹7,54,55,608 of the excess stock addition has been sustained. The company is evaluating the order and considering legal remedies, particularly regarding the taxation of the sustained amount at a special rate of 78% versus the normal rate of 34.944% already paid.

Mukka Proteins Limited has announced a further delay in the acquisition of Mukka Proteins Vietnam Co., Ltd. The acquisition, intended to secure 70% of the target company's share capital for up to ₹10,00,000, was initially expected to be completed by June 30, 2026. The delay is attributed to pending regulatory approvals in Vietnam. The new expected completion date is December 31, 2026. The company assures that necessary steps are being taken to finalize the acquisition.

Mukka Proteins Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter and three months period ending June 30, 2026. The decision aligns with the company's 'Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders' and SEBI (Prohibition of Insider Trading) Regulations, 2015. Designated persons and their immediate relatives are prohibited from trading during this period. The date of the board meeting to approve these financial results will be communicated separately.

Mukka Proteins Ltd has announced the completion of its strategic acquisition of a 51% stake in Delta Marine Products, a partnership firm, for ₹11.10 crore via capital contribution. This acquisition is part of Mukka Proteins' plan to expand its core business, focusing on capacity enhancement and operational optimization. Delta Marine Products is involved in the manufacturing of fish meal and fish oil. The transaction was completed on June 25, 2026. Delta Marine Products reported a turnover of ₹28.17 crore and a PAT of ₹(19.73) lakh for FY 2024-25. This is not a related party transaction.

Mukka Proteins Limited has submitted an application to BSE and NSE seeking in-principle approval for a preferential issue of 2,00,00,000 convertible warrants. The issue price is set at Rs. 23.50 per warrant, aggregating to Rs. 47,00,00,000. This preferential issue is subject to obtaining necessary approvals, including in-principle approval from the stock exchanges and shareholder consent. The company has also remitted a processing fee of Rs. 3,54,000 to the exchanges.

Mukka Proteins Ltd announced a strategic investment of up to ₹11.1 crore to acquire a 51% stake in Delta Marine Products, a partnership firm specializing in fish meal and fish oil manufacturing. This investment, approved by the Board of Directors on June 12, 2026, is part of Mukka Proteins' plan to expand its core business, optimize operations, and increase market reach. The acquisition is expected to be completed by September 30, 2026. Delta Marine Products reported a turnover of ₹28.17 crore and a net loss of ₹19.73 lakh in FY 2024-25. This move is not a related party transaction.

Mukka Proteins Ltd announced a strategic investment of up to ₹15 crore to acquire a 51% stake in Aqua Marine, a partnership firm specializing in manufacturing fish meals and fish oil. This investment, approved by the Board of Directors on June 12, 2026, aims to expand Mukka Proteins' core business through capacity enhancement and operational optimization. Aqua Marine reported a turnover of ₹32.15 crore and a PAT of ₹10.68 lakh in FY25. The acquisition is expected to be completed by September 30, 2026, and is not a related party transaction.

Mukka Proteins Ltd's Board of Directors met on June 12, 2026, approving the preferential issue of up to 2 crore Fully Convertible Warrants to non-promoter entities at Rs. 23.50 per warrant, aggregating Rs. 47 crore. These warrants are convertible into equity shares within 18 months, subject to shareholder approval. The company also approved draft postal ballot notices for seeking member approval and set the e-voting period from June 13 to July 12, 2026. Additionally, the Board sanctioned investments not exceeding Rs. 11.10 crore in Delta Marine Products and Rs. 15 crore in Aqua Marine, both partnership firms.

Mukka Proteins Ltd's Board of Directors has approved a preferential issue of up to 2 crore Fully Convertible Warrants to identified non-promoter entities at an issue price of ₹23.50 per warrant. This issue aims to raise approximately ₹47 crore. Each warrant is convertible into one equity share within 18 months, subject to shareholder and regulatory approvals. The company also approved the draft postal ballot notice and fixed the e-voting period. Additionally, Mukka Proteins will invest up to ₹11.10 crore in Delta Marine Products and ₹15 crore in Aqua Marine, both partnership firms.

Mukka Proteins Ltd has announced that its Board of Directors will convene on June 12, 2026. The primary agenda item is to consider and approve a proposal for raising funds through the issuance of securities. This could be via preferential issue, rights issue, or other suitable modes. Additionally, the company has closed its trading window from June 9, 2026, until 48 hours after the board meeting outcome for designated persons and their relatives, in compliance with SEBI regulations.